Skip to Main Content

Paper Details

Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.
Cancer Res
61
2014
AML, Dipyridamole, HMG-CoA, HMG-CoA reductase, HMG-CoA synthase 1, HMGCR, HMGCS1, MVA, SREBF2, SREBP2, Statins, acute myelogenous leukemia, cerebral ischemia, dipyridamole, hematologic malignancies, hypercholesterolemia, mevalonate, multiple myeloma, multiple myeloma and AML cell lines, myeloma and AML, normal peripheral blood mononuclear cells, patients, statin, statins, sterol, sterol regulatory element-binding transcription factor 2, tumor
Author NameAffiliation
Aleksandra A PandyraPrincess Margaret Cancer Centre, University of Toronto
Peter J MullenPrincess Margaret Cancer Centre
Manpreet KalkatPrincess Margaret Cancer Centre, University of Toronto
Zhihua LiPrincess Margaret Cancer Centre
Suzanne TrudelPrincess Margaret Cancer Centre, University of Toronto
Suzanne TrudelPrincess Margaret Cancer Centre, University of Toronto
Aaron D SchimmerPrincess Margaret Cancer Centre, University of Toronto
Linda Z PennPrincess Margaret Cancer Centre, University of Toronto
  • 1 - 8

Datasets

Release 1.2